SCHEMBL18248013

SCHEMBL18248013

O=C(O)[C@H](O)Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 4/20 0.53
PPARA Q07869 4/20 0.53
KDM6B O15054 1/20 0.51
GRB2 P62993 1/20 0.50
EPHX2 P34913 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.48
FPR2 P25090 1/20 0.48
SRD5A2 P31213 2/20 0.47
PTPN1 P18031 1/20 0.46
FFAR1 O14842 2/20 0.46
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44
CES2 O00748 2/20 0.44
CES1 P23141 2/20 0.44
FFAR2 O15552 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10170597 1.00 PPARG (0.53) PPARGPPARAKDM6BGRB2EPHX2
SCHEMBL11251320 0.85 FFAR1 (0.58) PPARGPPARAGRB2EPHX2L3MBTL1
SCHEMBL10891346 0.84 KDM6B (0.67) KDM6B
SCHEMBL2165859 0.81 KDM6B (0.47) PPARGPPARAKDM6BCES2
SCHEMBL18248097 0.81 KDM6B (0.51) KDM6BEPHX2
SCHEMBL18248019 0.81 KDM6B (0.51) KDM6BEPHX2
SCHEMBL2165857 0.81 KDM6B (0.47) PPARGPPARAKDM6BCES2
SCHEMBL23935482 0.80 PPARG (0.51) PPARGPPARAGRB2EPHX2L3MBTL1
SCHEMBL14947065 0.80 PPARA (0.56) PPARGPPARAGRB2EPHX2L3MBTL1
SCHEMBL148122 0.80 GRB2 (0.76) PPARGPPARAGRB2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12286455-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2025-04-29 US disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
EP-3397638-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2023-08-23 EP disclosed
CN-114891070-A Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-08-12 CN disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 US disclosed
US-11382949-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-07-12 US disclosed
CN-107835818-B Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-04-29 CN disclosed
CN-108699052-B Anthelmintic depsipeptide compounds 勃林格殷格翰动物保健美国公司 2022-04-29 CN disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-10081656-B2 Anthelmintic depsipeptide compounds MERIAL, INC. (US) 2018-09-25 US disclosed
WO-2018093920-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2018-05-24 WO disclosed
EP-3298027-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Merial, Inc. (US) 2018-03-28 EP disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 WO disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 WO disclosed
US-20170022253-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-01-26 US disclosed
WO-2016187534-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2016-11-24 WO disclosed
WO-2016187534-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2016-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 PPARG 3029/4885PPARA 3307/4885KDM6B 2834/4885
US-20170022253-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP PPARG 3698/4885PPARA 3734/4885KDM6B 1931/4885
US-11382949-B2 Anthelmintic depsipeptide compounds ENPP2, ROCK2, RRP12 PPARG 3652/4885PPARA 4049/4885KDM6B 2032/4885
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP PPARG 3670/4885PPARA 3876/4885KDM6B 1946/4885
US-10081656-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP PPARG 3698/4885PPARA 3734/4885KDM6B 1931/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP PPARG 3670/4885PPARA 3876/4885KDM6B 1946/4885
US-12286455-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP PPARG 3698/4885PPARA 3734/4885KDM6B 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.